162 related articles for article (PubMed ID: 35787856)
21. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Breen WG; Hathcock MA; Young JR; Kowalchuk RO; Bansal R; Khurana A; Bennani NN; Paludo J; Villasboas Bisneto JC; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
J Hematol Oncol; 2022 Mar; 15(1):36. PubMed ID: 35346315
[TBL] [Abstract][Full Text] [Related]
22. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity.
Breen WG; Young JR; Hathcock MA; Kowalchuk RO; Thorpe MP; Bansal R; Khurana A; Bennani NN; Paludo J; Bisneto JV; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
Blood Cancer J; 2023 Aug; 13(1):127. PubMed ID: 37591834
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Jain T; Knezevic A; Pennisi M; Chen Y; Ruiz JD; Purdon TJ; Devlin SM; Smith M; Shah GL; Halton E; Diamonte C; Scordo M; Sauter CS; Mead E; Santomasso BD; Palomba ML; Batlevi CW; Maloy MA; Giralt S; Smith E; Brentjens R; Park JH; Perales MA; Mailankody S
Blood Adv; 2020 Aug; 4(15):3776-3787. PubMed ID: 32780846
[TBL] [Abstract][Full Text] [Related]
26. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
[TBL] [Abstract][Full Text] [Related]
27. [The evaluation of modified cell infusion method to reduce febrile non-hemolytic transfusion reaction in CD(19) chimeric antigen receptor T cell threapy].
Wang J; Deng Q; Mu J; Jiang YY; Meng JX; Li YM
Zhonghua Nei Ke Za Zhi; 2019 Sep; 58(9):668-672. PubMed ID: 31461818
[No Abstract] [Full Text] [Related]
28. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
29. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
[TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
31. Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.
Pennese E; Salutari P; Carriero L; Restuccia F; De Filippis AF; De Luca G; Giancola R; Guardalupi F; Corradi G; Fabi B; Baldoni S; Di Ianni M
Front Immunol; 2023; 14():1272798. PubMed ID: 37841271
[TBL] [Abstract][Full Text] [Related]
32. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Mahmood SS; Riedell PA; Feldman S; George G; Sansoterra SA; Althaus T; Rehman M; Mead E; Liu JE; Devereux RB; Weinsaft JW; Kim J; Balkan L; Barbar T; Lee Chuy K; Harchandani B; Perales MA; Geyer MB; Park JH; Palomba ML; Shouval R; Tomas AA; Shah GL; Yang EH; Gaut DL; Rothberg MV; Horn EM; Leonard JP; Van Besien K; Frigault MJ; Chen Z; Mehrotra B; Neilan TG; Steingart RM
Eur Heart J; 2023 Jun; 44(22):2029-2042. PubMed ID: 36939851
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Johnsrud A; Craig J; Baird J; Spiegel J; Muffly L; Zehnder J; Tamaresis J; Negrin R; Johnston L; Arai S; Shizuru J; Lowsky R; Meyer E; Weng WK; Shiraz P; Rezvani A; Latchford T; Mackall C; Miklos D; Frank M; Sidana S
Blood Adv; 2021 Nov; 5(21):4465-4475. PubMed ID: 34521106
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
37. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Makita S; Yoshimura K; Tobinai K
Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
[TBL] [Abstract][Full Text] [Related]
38. Contrast-Associated Acute Kidney Injury in Endovascular Thrombectomy Patients With and Without Baseline Renal Impairment.
Diprose WK; Sutherland LJ; Wang MTM; Barber PA
Stroke; 2019 Dec; 50(12):3527-3531. PubMed ID: 31587663
[TBL] [Abstract][Full Text] [Related]
39. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Ghafouri S; Timmerman J; Larson S; Mead MD
Bone Marrow Transplant; 2021 Apr; 56(4):974-977. PubMed ID: 33168933
[No Abstract] [Full Text] [Related]
40. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
